GHO Capital closes €660 million private equity fund

25 November 2016

London, UK – GHO Capital, the European specialist investor in healthcare, today announces the successful final close for GHO Capital Fund I LP, a €660 million private equity fund which has been raised to seize the highly attractive and underpenetrated investment opportunity in European healthcare.

GHO Capital Fund I LP (“the Fund”) was significantly oversubscribed, exceeding its target of €500 million through strong support from a global investor base including leading pension funds, sovereign wealth funds, asset managers, insurance companies, fund of funds, family offices and high net worth individuals.

The Fund started investing in October 2015 and has made five investments to date: DNA Diagnostics Center, a leading DNA testing company focused on the development of innovative genetic testing products and services; Quotient Clinical, a provider of outsourced, early-stage drug development services to the pharmaceutical industry; Envision Pharma Group, a leading Medical Affairs-focused scientific communications and technology solutions provider; VISUfarma, a pan-European ophthalmic specialty pharmaceutical company; and Caprion Biosciences, the leading provider of proteomics and immune monitoring services to the pharmaceutical and biotechnology industry.

With a dedicated healthcare team of 10 investment professionals, GHO Capital’s complementary skill set combines traditional private equity and investment banking expertise with proven industrial capabilities. Backed by a global network of experts, and with a long-standing history of investment, transaction execution and senior operational roles in healthcare companies, GHO Capital is well-positioned to help ambitious management teams to deliver growth.

The partners at GHO Capital, commented:“We are very grateful for all the support we have received in realising our vision to create the leading European specialist healthcare investor and in successfully raising our first fund. From the beginning Drs. Mireille and Dennis Gillings shared that vision and laid the foundation for the firm’s creation with their invaluable support through their cornerstone, healthcare expertise and extensive networks and they have been joined by our industry advisors and the institutions who have invested in the Fund.”

GHO Capital was advised by London-based Rede Partners, a leading independent fund raising and secondary advisor to the private equity industry.

About GHO Capital
Global Healthcare Opportunities, or GHO Capital Partners LLP, was founded in 2014 as a specialist healthcare investment adviser based in London. Our vision is to apply global capabilities and perspectives to build a world-class healthcare specialist private equity firm by recognising and seizing the highly attractive and underpenetrated European market opportunity. We have a powerful combination of transaction, investment and industry skills which sets us apart from traditional private equity firms. For further information, please visit www.ghocapital.com.